MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors.

Zaaroor Levy, Mor; Rabinowicz, Noa; Yamila Kohon, Maia; Shalom, Avshalom; Berl, Ariel; Hornik-Lurie, Tzipi; Drucker, Liat; Tartakover Matalon, Shelly; Levy, Yair

Zaaroor Levy, Mor; Rabinowicz, Noa; Yamila Kohon, Maia; Shalom, Avshalom; Berl, Ariel; Hornik-Lurie, Tzipi; Drucker, Liat; Tartakover Matalon, Shelly; Levy, Yair.

Afiliación

Zaaroor Levy M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Rabinowicz N; Autoimmune Research Laboratory, Meir Medical Center, Kfar Saba 4428164, Israel.
Yamila Kohon M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Shalom A; Autoimmune Research Laboratory, Meir Medical Center, Kfar Saba 4428164, Israel.
Berl A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Hornik-Lurie T; Autoimmune Research Laboratory, Meir Medical Center, Kfar Saba 4428164, Israel.
Drucker L; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Tartakover Matalon S; Department of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.
Levy Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Biomedicines ; 10(3)2022 Mar 08.

Article en En | MEDLINE | ID: mdl-35327430

Palabras clave

biomarkers; complement; macitentan; miRNA; myofibroblasts; pulmonary arterial hypertension (PAH); systemic sclerosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Screening_studies Idioma: En Revista: Biomedicines Año: 2022 Tipo del documento: Article País de afiliación: Israel

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google